IL151615A0 - Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels - Google Patents

Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Info

Publication number
IL151615A0
IL151615A0 IL15161501A IL15161501A IL151615A0 IL 151615 A0 IL151615 A0 IL 151615A0 IL 15161501 A IL15161501 A IL 15161501A IL 15161501 A IL15161501 A IL 15161501A IL 151615 A0 IL151615 A0 IL 151615A0
Authority
IL
Israel
Prior art keywords
apomorphine
methods
plasma concentration
sexual dysfunction
concentration levels
Prior art date
Application number
IL15161501A
Other languages
English (en)
Original Assignee
Tap Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Holdings Inc filed Critical Tap Holdings Inc
Publication of IL151615A0 publication Critical patent/IL151615A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL15161501A 2000-03-20 2001-03-14 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels IL151615A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19054000P 2000-03-20 2000-03-20
PCT/US2001/040294 WO2001074358A1 (fr) 2000-03-20 2001-03-14 Methodes pour traiter des dysfonctions sexuelles avec de l'apomorphine a des taux de concentration de plasma determines

Publications (1)

Publication Number Publication Date
IL151615A0 true IL151615A0 (en) 2003-04-10

Family

ID=22701756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15161501A IL151615A0 (en) 2000-03-20 2001-03-14 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Country Status (18)

Country Link
US (1) US20020006933A1 (fr)
EP (1) EP1265609A4 (fr)
JP (1) JP2003533441A (fr)
KR (1) KR20030012852A (fr)
CN (1) CN1315177A (fr)
AU (1) AU2001253854A1 (fr)
BG (1) BG107185A (fr)
BR (1) BR0005797A (fr)
CA (1) CA2403791A1 (fr)
CZ (1) CZ20023427A3 (fr)
HU (1) HUP0301828A3 (fr)
IL (1) IL151615A0 (fr)
MX (1) MXPA02009237A (fr)
NO (1) NO20024442L (fr)
PL (1) PL365854A1 (fr)
SK (1) SK15112002A3 (fr)
WO (1) WO2001074358A1 (fr)
ZA (1) ZA200207113B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
CA2518102C (fr) * 2003-03-04 2009-05-12 Tanabe Seiyaku Co., Ltd. Preparation en poudre pour l'administration nasale
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CA3115378A1 (fr) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Films sublinguaux comprenant de l'apomorphine et une base organique
EP2545905A1 (fr) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
NZ703341A (en) * 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US20140377365A1 (en) * 2013-06-19 2014-12-25 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
EP1265609A1 (fr) 2002-12-18
HUP0301828A2 (hu) 2003-09-29
JP2003533441A (ja) 2003-11-11
CZ20023427A3 (cs) 2003-11-12
EP1265609A4 (fr) 2005-02-09
ZA200207113B (en) 2004-01-28
MXPA02009237A (es) 2004-04-05
BG107185A (bg) 2003-05-30
CA2403791A1 (fr) 2001-10-11
NO20024442L (no) 2002-11-20
CN1315177A (zh) 2001-10-03
SK15112002A3 (sk) 2003-06-03
HUP0301828A3 (en) 2006-02-28
PL365854A1 (en) 2005-01-10
AU2001253854A1 (en) 2001-10-15
BR0005797A (pt) 2001-10-16
WO2001074358A1 (fr) 2001-10-11
US20020006933A1 (en) 2002-01-17
KR20030012852A (ko) 2003-02-12
NO20024442D0 (no) 2002-09-17

Similar Documents

Publication Publication Date Title
IL151615A0 (en) Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels
PL377729A1 (pl) Sposób leczenia dysfunkcji seksualnej
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
MXPA02005737A (es) Dispositivo y metodo para tratar agua con ozono generdo mediante electrolisis del agua.
EP1541532A4 (fr) Processus de traitement des eaux usees grace a un procede de boues actives comprenant un traitement d'atomisation lineaire
IL164352A0 (en) Methods for treating tweak-related conditions
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
EP1310461A4 (fr) Proc d de traitement d'eaux us es organiques
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU3894600A (en) Method of treating sexual dysfunction
EP1452492A4 (fr) Procede de traitement d'un residu liquide contenant du cyanure
GB2389455B (en) Ion implantation apparatus equipped with plasma shower and ion implantation method
IL155667A0 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
AU6605800A (en) Melanocortin receptor-3 ligands to treat sexual dysfunction
PL371604A1 (en) Method for treating water in order to reduce the metal ion concentration thereof
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
EP1260486A4 (fr) Procede de traitement des eaux d'egout organiques
PL362980A1 (en) Treatment of sexual dysfunction
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
PL376350A1 (en) Sludge treatment method
AU2001284901A1 (en) Method for treating metal contaminated water
SG110202A1 (en) Method of treating wastewater containing flouride ion
AU2003277296A8 (en) Compositions and methods for treating sexual dysfunction